Common use of Public Float Calculation Clause in Contracts

Public Float Calculation. As of the close of trading on the Principal Market on April 8, 2020, the aggregate market value of the outstanding voting and non-voting common equity (as defined in Rule 405) of the Company held by persons other than affiliates of the Company (pursuant to Rule 144, those that directly, or indirectly through one or more intermediaries, control, or are controlled by, or are under common control with, the Company) (the “Non-Affiliate Shares”), was approximately $ $23,954,504.90 (calculated by multiplying (x) the price at which the common equity of the Company was last sold on the Principal Market on February 12, 2020 by (y) the number of Non-Affiliate Shares outstanding on April 8, 2020).

Appears in 1 contract

Samples: Securities Purchase Agreement (Trovagene, Inc.)

AutoNDA by SimpleDocs

Public Float Calculation. As of the close of trading on the Principal Market on April 8October 12, 2020, the aggregate market value of the outstanding voting and non-voting common equity (as defined in Rule 405) of the Company held by persons other than affiliates of the Company (pursuant to Rule 144, those that directly, or indirectly through one or more intermediaries, control, or are controlled by, or are under common control with, the Company) (the “Non-Affiliate Shares”), was approximately $ $23,954,504.90 59,860,436 (calculated by multiplying (x) the price at which the common equity of the Company was last sold on the Principal Market on February 12October 5, 2020 by (y) the number of Non-Affiliate Shares outstanding on April 8October 12, 2020).

Appears in 1 contract

Samples: Securities Purchase Agreement (Aridis Pharmaceuticals, Inc.)

Public Float Calculation. As of the close of trading on the Principal Market on April 8March 27, 2020, the aggregate market value of the outstanding voting and non-voting common equity (as defined in Rule 405) of the Company held by persons other than affiliates of the Company (pursuant to Rule 144, those that directly, or indirectly through one or more intermediaries, control, or are controlled by, or are under common control with, the Company) (the “Non-Affiliate Shares”), was approximately $ $23,954,504.90 22,215,410 (calculated by multiplying (x) the price at which the common equity of the Company was last sold on the Principal Market on February 12, 2020 by (y) the number of Non-Affiliate Shares outstanding on April 8March 27, 2020).

Appears in 1 contract

Samples: Securities Purchase Agreement (Trovagene, Inc.)

Public Float Calculation. As of the close of trading on the Principal Market on April 8May 22, 2020, the aggregate market value of the outstanding voting and non-voting common equity (as defined in Rule 405) of the Company held by persons other than affiliates of the Company (pursuant to Rule 144, those that directly, or indirectly through one or more intermediaries, control, or are controlled by, or are under common control with, the Company) (the “Non-Affiliate Shares”), was approximately $ $23,954,504.90 27,829,062 (calculated by multiplying (x) the price at which the common equity of the Company was last sold on the Principal Market on February 12May 20, 2020 by (y) the number of Non-Affiliate Shares outstanding on April 8May 22, 2020).

Appears in 1 contract

Samples: Securities Purchase Agreement (Cardiff Oncology, Inc.)

Public Float Calculation. As of the close of trading on the Principal Market on April 8September 13, 20202023, the aggregate market value of the outstanding voting and non-voting common equity (as defined in Rule 405) of the Company held by persons other than affiliates of the Company (pursuant to Rule 144, those that directly, or indirectly through one or more intermediaries, control, or are controlled by, or are under common control with, the Company) (the “Non-Affiliate Shares”), was approximately $ $23,954,504.90 51,218,719 (calculated by multiplying (x) the price at which the common equity of the Company was last sold on the Principal Market on February 12August 29, 2020 2023 by (y) the number of Non-Affiliate Shares outstanding on April 8August 31, 20202023).

Appears in 1 contract

Samples: Securities Purchase Agreement (OKYO Pharma LTD)

Public Float Calculation. As of the close of trading on the Principal Market on April 8May 9, 20202019, the aggregate market value of the outstanding voting and non-voting common equity (as defined in Rule 405) of the Company held by persons other than affiliates of the Company (pursuant to Rule 144, those that directly, or indirectly through one or more intermediaries, control, or are controlled by, or are under common control with, the Company) (the “Non-Affiliate Shares”), was approximately $ $23,954,504.90 24,773,668 (calculated by multiplying (x) the price at which the common equity of the Company was last sold on the Principal Market on February 12April 1, 2020 2019 by (y) the number of Non-Affiliate Shares outstanding on April 8May 9, 20202019).

Appears in 1 contract

Samples: Securities Purchase Agreement (Trovagene, Inc.)

AutoNDA by SimpleDocs

Public Float Calculation. As of the close of trading on the Principal Market on April 8December __, 20202023, the aggregate market value of the outstanding voting and non-voting common equity (as defined in Rule 405) of the Company held by persons other than affiliates of the Company (pursuant to Rule 144, those that directly, or indirectly through one or more intermediaries, control, or are controlled by, or are under common control with, the Company) (the “Non-Affiliate Shares”), was approximately $ $23,954,504.90 ______ (calculated by multiplying (x) the price at which the common equity of the Company was last sold on the Principal Market on February 12November 3, 2020 2023 by (y) the number of Non-Affiliate Shares outstanding on April 8December __, 20202023).

Appears in 1 contract

Samples: Securities Purchase Agreement (OKYO Pharma LTD)

Public Float Calculation. As of the close of trading on the Principal Market on April 83, 20202019, the aggregate market value of the outstanding voting and non-voting common equity (as defined in Rule 405) of the Company held by persons other than affiliates of the Company (pursuant to Rule 144, those that directly, or indirectly through one or more intermediaries, control, or are controlled by, or are under common control with, the Company) (the “Non-Affiliate Shares”), was approximately $ $23,954,504.90 21,848,925 (calculated by multiplying (x) the price at which the common equity of the Company was last sold on the Principal Market on February 12March 11, 2020 2019 by (y) the number of Non-Affiliate Shares outstanding on April 83, 20202019).

Appears in 1 contract

Samples: Securities Purchase Agreement (Trovagene, Inc.)

Public Float Calculation. As of the close of trading on the Principal Market on April 8August 19, 20202019, the aggregate market value of the outstanding voting and non-voting common equity (as defined in Rule 405) of the Company held by persons other than affiliates of the Company (pursuant to Rule 144, those that directly, or indirectly through one or more intermediaries, control, or are controlled by, or are under common control with, the Company) (the “Non-Affiliate Shares”), was approximately $ $23,954,504.90 17,059,560 (calculated by multiplying (x) the price at which the common equity of the Company was last sold on the Principal Market on February 12August 19, 2020 2019 by (y) the number of Non-Affiliate Shares outstanding on April 8August 19, 20202019).

Appears in 1 contract

Samples: Securities Purchase Agreement (Trovagene, Inc.)

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!